Canterbury DHB
Patients rarely respond to imatinib or interferon α.
Prognosis is variable, but generally thought to be poor, and transformation to acute leukemia is common. One small series6 gave median survival of 22.2 months.
Adverse risk factors include:
Topic Code: 537415